4,134,969 Shares in Century Therapeutics, Inc. $IPSC Acquired by Trails Edge Capital Partners LP

Trails Edge Capital Partners LP purchased a new stake in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 4,134,969 shares of the company's stock, valued at approximately $10,130,674. Century Therapeutics accounts for approximately 0.0% of Trails Edge Capital Partners LP's holdings, making the stock its 25th biggest holding. Trails Edge Capital Partners LP owned about 2.29% of Century Therapeutics at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Seven Fleet Capital Management LP acquired a new position in shares of Century Therapeutics during the first quarter worth $9,826,000. Commodore Capital LP acquired a new position in shares of Century Therapeutics during the 1st quarter worth about $19,652,000. Versant Venture Management LLC bought a new position in Century Therapeutics in the first quarter valued at approximately $27,495,000. Rock Springs Capital Management LP acquired a new stake in Century Therapeutics in the 1st quarter worth about $2,948,000. Finally, DV Trading LLC acquired a new stake in shares of Century Therapeutics during the 1st quarter valued at $3,164,000. Institutional investors and hedge funds own 50.20% of the company's stock.

Analyst Ratings Changes

IPSC has been the topic of several research analyst reports. Wall Street Zen cut shares of Century Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 27th. Weiss Ratings restated a "sell (d-)" rating on shares of Century Therapeutics in a research note on Thursday, July 2nd. Finally, Mizuho began coverage on Century Therapeutics in a report on Wednesday, May 27th. They issued an "outperform" rating and a $8.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $4.75.

Century Therapeutics Stock Performance

Century Therapeutics stock traded down $0.20 during trading hours on Friday, hitting $2.03. 629,312 shares of the stock were exchanged, compared to its average volume of 1,369,619. Century Therapeutics, Inc. has a 12 month low of $0.44 and a 12 month high of $3.04. The business's 50-day moving average is $2.17 and its two-hundred day moving average is $2.22. The stock has a market capitalization of $367.58 million, a P/E ratio of -2.18 and a beta of 1.57.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.06). On average, equities analysts predict that Century Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.